--------------------
human-full
Thrombectomy
reviewAbstract
AVGs
AVFs).Arteriovenous
Thrombectomy
rheolytic
65–85
hemoconcentration
Cannulation
REF].Thrombosed
Thrombus
Thrombosed
AVGs
AVFs
https://cdt.amegroups.com/article/view/10.21037/cdt-21-523/rc
--------------------
continue
AVGs
AVFs
rheolytic
--------------------
human-cont
65–85
hemoconcentration
Cannulation
REF].Thrombosed
Thrombus
Thrombosed
AVGs
AVFs
https://cdt.amegroups.com/article/view/10.21037/cdt-21-523/rc
--------------------
explain
AVGs
AVFs
AVGs
AVFs
--------------------
create
AVFs
AVGs
AVFs
AVGs
AVFs
hemoconcentration
Thrombosed
Thrombus
AVFs
AVGs
AVGs
AVFs
--------------------
human-full
Disease-2019
StatesAbstract
disease-2019
disease-2019
78%.5
CSDH)8
1Structural
equipment.(From
Lovinsky
Bime
Wisnivesky
2020;202(7):943
949.)Structural
--------------------
continue
--------------------
human-cont
disease-2019
78%.5
CSDH)8
1Structural
equipment.(From
Lovinsky
Bime
Wisnivesky
2020;202(7):943
949.)Structural
--------------------
create
disease-2019
--------------------
explain
--------------------
create
eADO
eADO
eATP
eATP
eATP
eADO
eATP
eADO
eATP
immunosurveillance
adenosinergic
adenosinergic
adenosinergic
eADO
adenosinergic
adenosinergic
adenosinergic
--------------------
human-full
adenosinergic
therapyAbstract
eADO
eADO
eATP
eATP
eATP
eADO
eATP
eADO
immunosurveillance
eATP
adenosinergic
adenosinergic
immunoregulation
eATP
eATP
eATP
purinoceptor
eATP
eADO
ectonucleotidases
REF].eADO
signaling.eADO
eATP
ectonucleotidases
eATP
CD39
ectonucleoside
diphosphohydrolase
eADO
CD73
5′-nucleotidase
eAMP
eADO
eAMP
eATP
NDPK
REF].The
eADO
ectohydrolase
CD203a
ectonucleotide
ADPR
CD203a
ADPR
CD73
eADO
CD73
TNAP
eAMP
eADO
REF].Analogous
eATP
eADO
eADO
eADO
concentrative
CNT1/2
equilibrative
ENT1/2
cADA
SAHH
eATP
CD39
CD73
eADO
eADO
eADO
eADO
CD39
CD73
eADO
CD73
eADO
eADO
eADO
--------------------
explain
adenosinergic
eADO
eADO
eATP
eATP
eADO
eATP
eADO
eATP
immunosurveillance
immunoregulation
eATP
eATP
eATP
eADO
ectonucleotidases
eADO
ectonucleotidases
eAMP
eADO
eADO
eADO
eADO
eADO
adenosinergic
eATP
eADO
--------------------
continue
adenosinergic
eADO
eATP
eATP
eATP
eADO
eATP
eADO
eATP
adenosinergic
adenosinergic
adenosinergic
adenosinergic
adenosinergic
--------------------
human-cont
immunoregulation
eATP
eATP
eATP
purinoceptor
eATP
eADO
ectonucleotidases
REF].eADO
signaling.eADO
eATP
ectonucleotidases
eATP
CD39
ectonucleoside
diphosphohydrolase
eADO
CD73
5′-nucleotidase
eAMP
eADO
eAMP
eATP
NDPK
REF].The
eADO
ectohydrolase
CD203a
ectonucleotide
ADPR
CD203a
ADPR
CD73
eADO
CD73
TNAP
eAMP
eADO
REF].Analogous
eATP
eADO
eADO
eADO
concentrative
CNT1/2
equilibrative
ENT1/2
cADA
SAHH
eATP
CD39
CD73
eADO
eADO
eADO
eADO
CD39
CD73
eADO
CD73
eADO
eADO
eADO
--------------------
human-full
ENHANceAbstract
sarcopenic
AgeiNg
ENHANce
sarcopenic
65y
rho(ρ
SarQoL).In
5.4y
2.8–5.6
2.2–4.4
aLM
ρ:-0.439
aLM
ρ:0.388
SarQoL
-0.426
0.024).Although
s12877
04007
REF]).Detailed
sarcopenic
sarcopenic
sarcopenic
EWGSOP2
sarcopenic
--------------------
continue
Jentoft
AgeiNg
ENHANce
sarcopenic
sarcopenic
39(1_suppl
18S-32S.
Jentoft
Bahat
Boirie
Cederholm
--------------------
human-cont
REF]).Detailed
sarcopenic
sarcopenic
sarcopenic
EWGSOP2
sarcopenic
--------------------
explain
ENHANce
sarcopenic
sarcopenic
sarcopenic
--------------------
create
sarcopenic
sarcopenic
--------------------
explain
--------------------
human-full
PASC)Abstract
PASC.The
https://recovercovid.org/protocols
PASC.The
Nsps
--------------------
create
--------------------
human-cont
PASC.The
https://recovercovid.org/protocols
PASC.The
Nsps
REF].Several
REF].Formation
thrombogenic
REF].Although
24–72
PASC?Monocytes
REF].Indeed
hyperactivated
REF].In
CCL3
hyperinflammation
siltuximab
REF].There
hyperinflammation
HLADR+
CD14−
immunophenotyping
REF].Altogether
monocyte-
hyperinflammation
PASC.Mast
extrafollicular
REF].Several
2021a
IFNg
TRMs
sequalae
CoV-2-
RNAemia
immunophenotyping
TRBV11
superantigen
superantigen
TRBV
TRBV
REF].Figure
REF].The
overreactive
Biorender.com
hyperinflammatory
Favalli
2020b
REF].The
FcR
2021c
2021b
Autoantibody
hyperinflammation
extrafollicular
extrafollicular
extrafollicular
REF].In
2022a
2022b
receptors.[REF
autoreactivity
PASC.Much
--------------------
continue
immunopathological
